Organization

Nottingham Trent University

1 clinical trial

1 abstract

Abstract
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
Org: Nottingham Univ City Hosp NHS Trust, Van Geest Cancer research Centre, School of Science and Technology Nottingham Tr, Nottingham University Hospitals NHS Trust, Nottingham Trent University,